Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Trial Details

NCT ID
NCT07520006
Phase
PHASE1 / PHASE2
Sponsor
Nurix Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • NX-5948
  • venetoclax
  • rituximab
  • obinutuzumab
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Coral Gables, Florida, United States|25.72149,-80.26838
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Las Vegas, Nevada, United States|36.17497,-115.13722
  • Belleville, New Jersey, United States|40.79371,-74.15014

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Measurable disease by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →